Tyrosine Kinase Inhibitor

Advancing Treatment in De Novo BCR::ABL1+ Acute Myeloid Leukemia: The Impact of Combining Intensive Chemotherapy with Tyrosine Kinase Inhibitors

The addition of tyrosine kinase inhibitors to intensive chemotherapy markedly improves remission rates and overall survival in patients with de novo BCR::ABL1+ acute myeloid leukemia, suggesting a new standard of care approach.